Oct 25 (Reuters) - Prometic Life Sciences Inc PLI.TO -
* Prometic receives fast track designation for PBI-4050 in development for idiopathic pulmonary fibrosis (IPF)
* Prometic Life Sciences Inc - fast track designation follows recent FDA approval of pivotal Phase 2/3 clinical trial in IPF